Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 63

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 63
---
 at all. If we are unable to obtain a necessary license to a third-party patent on
commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could
in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to
the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications
is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our current or future product
candidates.

Parties making claims against
us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize
our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be
a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may
have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses
from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary
expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable
terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our
research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on
reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could
harm our business significantly.

We may not be successful in obtaining or
maintaining necessary rights through acquisitions and in-licenses to product components and processes that may be required to complete
development of and commercialize our Alpha DaRT Technology.

Presently we own various patents
and patent applications related to our Alpha DaRT technology and, other than our collaboration agreement with MIM with respect to MIM’s
own software offerings, we are not a party to any license agreements with third parties that enable us to utilize third-party technology.
Because our Alpha DaRT technology, including the use in connection with other therapies, may require the use of proprietary rights held
by third parties in the future, the growth of our business will likely depend in part on our